$CCAP

Crescent Capital BDC (CCAP) Misses Q3 Earnings and Revenue Estimates

Crescent Capital BDC (CCAP) delivered earnings and revenue surprises of -2.13% and -2.52%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Original reporting
Zacks Commentary · Zacks Equity Research
Published Nov 12, 2025, 10:40 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Nov 13, 2025, 12:32 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Crescent Capital BDC (CCAP) Misses Q3 Earnings and Revenue Estimates — source image
Decision brief

The 30-second read

$CCAPBearishMed
01

Why it matters

The earnings miss could lead to short-term price declines, but long-term fundamentals and sector trends should be considered.

02

Market read

The news is relevant for traders with exposure to the financial sector, especially those holding or considering positions in BDCs.

03

What to watch

Potential for sector-wide recovery driven by broader economic factors or policy changes.

Timing: Immediate; news published within the last 24 hours.

Background

Crescent Capital BDC reported Q3 earnings and revenue below analyst estimates, raising concerns about near-term performance.

Company-level read

Ticker impact

$CCAPBearishHigh confidence
Context

Primary focus of the news, as it reports Crescent Capital BDC's earnings miss.

Expected impact

Moderate decline expected in the short term, approximately 2-4%.

Evidence & confidence

Earnings misses often lead to immediate price declines; the magnitude aligns with historical reactions to similar reports.

$GLADNeutralMedium confidence
Context

Sentiment data indicates a neutral outlook, with minimal immediate impact.

Expected impact

Minimal impact expected, negligible price movement.

Evidence & confidence

Neutral sentiment coupled with low relevance indicates limited trading significance.

Market effects

Potential negative sentiment in the financial sector, especially among similar BDCs.

Limited regional impact; primarily affects US-based financial stocks.

Low; impact is confined to specific sector and company.

Counterpoint

The earnings miss may be a temporary setback; fundamentals remain strong, and long-term investors could view this as a buying opportunity.

Key entities

  • Crescent Capital BDC

    A business development company providing debt and equity financing to middle-market companies.

Related articles

$CCAPMed

Crescent Capital BDC, Inc. (CCAP): Results of Operations and Financial Condition

Crescent Capital BDC, Inc. (CCAP) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ccap-ex99_1.htm EX-99.1 EX-99.1 Crescent Capital BDC, Inc. Reports Second Quarter 2026 Earnings Results; Declares a Third Quarter Base Dividend of $0.34 Per Share LOS ANGELES, August 10, 2026 — Crescent Capital BDC, Inc. (“Crescent BDC” or “Company”) (NASDAQ: CCAP) toda

$GLADMed

Gladstone Capital Corporation Reports Financial Results for its Third Quarter Ended June 30, 2026

Gladstone Capital Corporation (Nasdaq:GLAD) reported Q3 results for the quarter ended June 30, 2026. Net investment income was $11.0 million, or $0.49 per share, down from $11.8 million, or $0.52. Total interest income rose to $24.3 million. Total investments at fair value were $953.3 million and NAV per common share was $21.50. The board declared $0.45 common distribution for the quarter.

$GLADMed

GLADSTONE CAPITAL CORP (GLAD): Results of Operations and Financial Condition

GLADSTONE CAPITAL CORP (GLAD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d115483dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Gladstone Capital Corporation Reports Financial Results for its Third Quarter Ended June 30, 2026 McLean, VA, August 4, 2026: Gladstone Capital Corporation (Nasdaq: GLAD) (the “Company”) today announced earnings for its thi

$GLADMed

Gladiator’s Cub assays highlight historical copper belt

Gladiator Metals reported new step-out drill assays at its Whitehorse project in Yukon, saying Cub East extends high-grade copper-gold-silver mineralization. Hole BCG-035 returned 32 m at 1.36% Cu, 0.63 g/t Au and 10.93 g/t Ag, and BCG-024 returned 32.7 m at 1.06% Cu, 0.44 g/t Au and 6.37 g/t Ag. The company plans more drilling and cites prior Whitehorse belt production.

$GLADMedAI 8/10

Gladiator Metals Corp.: Gladiator Announces Closing of Institutional C$35M Private Placement

Gladiator Metals Corp. (TSXV: GLAD, OTCQB: GDTRF) said it closed a BlackRock-led non-brokered private placement raising C$35.04M. It issued 7M charity flow-through shares at C$3.87 and 3M non-flow-through shares at C$2.65. Proceeds will fund 2026-2027 exploration at the Whitehorse Copper Project and working capital; finders received C$556,500 plus warrants.

$JNJMedAI 8/10

Is Johnson & Johnson’s $5.5 Billion Talc Settlement a Buy Signal, or Is the Legal Risk Far From Over?

Johnson & Johnson (JNJ) proposed a $5.5B settlement for 76,000 talc-related lawsuits, but it requires 95% claimant approval and may exceed this amount. The company has $21B in cash and expects to pay $3B in 2027, with further payments starting in 2028. A judge's recent ruling may strengthen JNJ's legal position. Investors weigh the benefit of reduced uncertainty against potential higher costs.